News Johnson & Johnson

Equities

JNJ

US4781601046

Market Closed - Nyse Other stock markets 04:00:02 2024-04-15 pm EDT			5-day change	1st Jan Change
147.6 ^USD	+0.05%		-2.64%	-5.84%

01:16pm	Rwanda joins other African countries in recalling J&J children's cough syrup	RE
01:08pm	US Equity Investors to Focus on Quarterly Earnings This Week as Geopolitical Risks Look Contained Despite Iran Attack	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB	08:27am	AQ
Rwanda joins other African countries in recalling J&J children's cough syrup	07:16am	RE
US Equity Investors to Focus on Quarterly Earnings This Week as Geopolitical Risks Look Contained Despite Iran Attack	07:08am	MT
Equity Futures Gain Pre-Bell Ahead of Busy Earnings Week; Asia Down, Europe Rises	07:02am	MT
University of Oregon: Options can lower vaccine hesitancy for COVID-19, other diseases	06:47am	AQ
S&P 500 Posts Second Consecutive Weekly Drop Led by Financials Amid Higher-Than-Expected Consumer Prices	Apr. 12	MT
Johnson & Johnson - Unique molecular properties of nipocalimab enabling differentiated potential in treating generalized myasthenia gravis to be presented at American Academy of Neurology's 2024 Annual Meeting	Apr. 12	AQ
NAFDAC Raises Alarm Over Fake Anti-Bacteria Injection, Deadly Cough Syrup	Apr. 12	AQ
Kenya, Nigeria Recall Children's Cough Syrup Over Toxic Substance	Apr. 12	AQ
US Equity Markets Close Mixed After March Producer Price Inflation Data	Apr. 11	MT
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 11	MT
Kenya recalls J&J children's cough syrup over suspected toxicity	Apr. 11	RE
Top Midday Gainers	Apr. 11	MT
J&J: presents results on nipocalimab	Apr. 11	CF
Kenya recalls J&J children's cough syrup over suspected toxicity	Apr. 11	RE
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Another Key Inflation Report	Apr. 11	MT
Johnson & Johnson Announces Planned Presentation of New Non-Clinical Studies	Apr. 11	CI
Rallybio Corporation Announces Collaboration with Johnson & Johnson	Apr. 10	CI
Nigeria recalls J&J children's cough syrup over toxic substance	Apr. 10	RE
Morgan Stanley Trims Price Target on Johnson & Johnson to $168 From $169, Keeps Equalweight Rating	Apr. 09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST